Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic’, inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. The invention further provides use of a sulfated oligosaccharide in the preparation of a medicament for the treatment of acute and chronic inflammatory disorders of the airways of mammals. The invention yet further provides use of a sulfated oligosaccharide to preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to new polysulfated glycosides of formula (I), the salts thereof formed with alkali metals or alkaline-earth metals, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.

Abstract: The invention relates to new stereoisomeric 1,4;3,6-dianhydro-2,5-diazido-2,5-dideoxy-hexitols of the Formula I.These compounds can be prepared by(a) reacting a hexitol derivative of the general Formula II /wherein R is a mesyl or tosyl group/ in an aqueous or anhydrous organic solvent with an alkali metal azide or ammonium azide; or(b) mesylating or tosylating a compound of the Formula III and treating the mixed ester of the general Formula IV thus obtained /wherein R is as stated above/ with a base; or(c) subjecting a compound of the Formula III to debenzoylation and subsequently to partial esterification and treating the compound of the general Formula V thus obtained /wherein R is as stated above/ with a base.The new compounds of the Formula I possess valuable hypnotic properties and can be used in therapy.

Abstract: The invention relates to 1,6-dimesyl-3,4-dimethyl-D-mannitol of the formula (I), ##STR1## wherein Ms is mesyl and Me is methyl. This compound is a potent cytostatic agent which can be used to advantage in the therapy of various tumorous diseases.1,6-Dimesyl-3,4-dimethyl-D-mannitol is prepared according to the invention by subjecting 3,4-dimethyl-D-mannitol to partial mesylation followed by acylation, and splitting off the acyl groups of the resulting compound of the general formula (III), ##STR2## wherein Ms and Me are as defined above and R is a saturated lower aliphatic group, with an acidic alcohol.